In BRAF-driven melanomas, combination of BRAF, MEK, and immune checkpoint inhibition through PD-L1 inhibitors enhanced cancer cell death and displayed efficacy in early clinical trials for metastatic melanoma (153, 154). Here, CD274 is linked to melanoma.